Data / Drug companies / Milrinone lactate
Milrinone lactate: 12 companies and 29 products in the FDA NDC directory
Milrinone lactate is listed in the FDA National Drug Code Directory by 12 companies, with 29 products in commercial distribution. 29 of the products (100.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection, solution, and the newest product started marketing on June 5, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 12
- Products
- 29
- Generic (ANDA) products
- 29 (100.0%)
- Application numbers
- 8
- Routes
- Intravenous
- openFDA record search
- api.fda.gov
Companies that list milrinone lactate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Hikma Pharmaceuticals USA Inc. | 6 | injection, solution | Generic drugs (ANDA) | December 3, 2010 |
| Armas Pharmaceuticals Inc. | 3 | injection, solution | Generic drugs (ANDA) | April 5, 2023 |
| Caplin Steriles Limited | 3 | injection, solution | Generic drugs (ANDA) | February 14, 2025 |
| Mullan Pharmaceutical Inc. | 3 | injection, solution | Generic drugs (ANDA) | September 18, 2023 |
| Shandong New Time Pharmaceutical Co., Ltd. | 3 | injection, solution | Generic drugs (ANDA) | June 5, 2025 |
| Somerset Therapeutics, LLC | 3 | injection, solution | Generic drugs (ANDA) | September 23, 2022 |
| Baxter Healthcare Corporation | 2 | injection, solution | Generic drugs (ANDA) | May 28, 2002 |
| Gland Pharma Limited | 2 | injection, solution | Generic drugs (ANDA) | July 16, 2020 |
| Fresenius Kabi USA, LLC | 1 | injection, solution | Generic drugs (ANDA) | August 1, 2002 |
| Hospira, Inc. | 1 | injection, solution | Generic drugs (ANDA) | March 31, 2015 |
| Meitheal Pharmaceuticals Inc. | 1 | injection, solution | Generic drugs (ANDA) | March 24, 2020 |
| Sagent Pharmaceuticals | 1 | injection, solution | Generic drugs (ANDA) | January 15, 2021 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 29 | 100% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 29 | 100% |
Pharmacologic classes
| Class | Products |
|---|---|
| Phosphodiesterase 3 Inhibitor | 29 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.